PlasmaGen Biosciences: Leading the Way in Plasma-Derived Therapies

The Bengaluru-based biopharma company PlasmaGen Biosciences has successfully secured Rs 150 crore in funding, with ViNS Bioproducts leading the investment round. Participation also came from high-net-worth individuals, family offices, pharma entrepreneurs, and existing investors. This startup, supported by Eight Road Ventures, attained a valuation surpassing Rs 1,500 crore. To date, PlasmaGen has raised over Rs 600 crore from various investors, including Fidelity’s FIL Capital Investments, Eight Roads Ventures, and F-Prime Capital.

Utilisation of Funds for Expansion

PlasmaGen Biosciences announced that the funds will facilitate the scaling of its international operations, broadening its product offerings, and enhancing both manufacturing and leadership capabilities.

About PlasmaGen Biosciences

Founded in 2010, PlasmaGen Biosciences is dedicated to producing and marketing plasma-derived therapies such as Immunoglobulin, Albumin, and clotting factors. The company’s efforts aim to resolve India’s demand-supply challenges for these essential medicines. It operates a state-of-the-art fractionation facility in Kolar, Karnataka, with the objective of achieving self-sufficiency in plasma products while focusing on sectors like neurology, hematology, and critical care.

International Expansion Plans

PlasmaGen has identified distribution relationships in prominent export markets and is actively pursuing regulatory certifications necessary for initiating international sales. While continuing to focus on India, the company works towards expanding its services to hospitals and clinicians through a robust cold-chain distribution network.

Operational Milestones

The company commenced its commercial activities in 2024 at its plasma fractionation facility located in Kolar, near Bengaluru. PlasmaGen claims that this setup is among the very few of its kind in the nation and positions itself as the first dedicated plasma biopharma player. Since launching operations in Kolar, the firm has reported significant revenue advancement and is strategically preparing to enter international markets.